Shots:

• Aerie to receive $88M up front, $77M in development, regulatory & sales milestones & is also eligible to receive additional consideration ~25% of the products net sales along with royalties
• Santen will be responsible for sales, marketing and pricing decisions related to the products & will lead the development, commercialization costs & activities in the countries except a post-marketing clinical study to be conducted by Aerie for Roclanda in the EU
• Aerie will be responsible for the manufacture & supply of products utilizing the Athlone, Ireland plant. Rhopressa & Rocklatan are approved in the US & EU which is also known as Rhokiinsa & Roclanda, respectively

Ref: Aerie Pharmaceuticals | Image: Aerie